Risk assessment of endocrine disrupting substances can be used if requisite and sufficient data on environmental exposure, the effects on sensitive species and life stages, and where relevant, delayed ...

EPA’s risk assessment process is built around the assumption that chemicals exhibit greater effects at higher concentrations. A growing number of studies, however, have shown that lower doses of some ...

April 12, 2011 — The Endocrine Society has issued clinical guidelines for the endocrine assessment and treatment of pituitary incidentaloma that indicates surgical therapy under some conditions.

Growth hormone insensitivity (GHI) describes a range of disorders in which there is resistance to the actions of growth hormone. This review focuses on three areas where advances contribute to ...

Please provide your email address to receive an email when new articles are posted on . The Endocrine Self-Assessment Program In-Training Examination is a strong predictor of pass/fail outcomes on the ...

The EU Commission jointly commissioned the two European authorities to prepare common guidelines as to how the hazard-based criteria can be implemented practically. Endocrine disruptors are chemicals ...

Principles of endocrinology need to be applied to strengthen the safety assessment of endocrine disrupting chemicals (EDCs), a statement from the US Endocrine Society concludes. “The Endocrine Society ...

Newly developed chemical substances or cosmetics can be distributed only after passing the risk assessment in human and environment. The developed product distribution is prohibited if it cannot pass ...

Analyzing correlates for cervical cancer awareness in Mauritania, Madagascar, and Benin from the Demographic Health Survey (DHS): 2017-2022. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

Thyroid and breast cancers are common, affecting women more than men. In their recent review article, Halada et al. detail inter-relationships between these two cancers -- common signaling pathways, ...

Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial The approval was ...